Abstract
In a meta-analysis published in June 2003, we reported that new and old classes of antihypertensive drugs had similar long-term efficacy and safety. Furthermore, we observed that in clinical trials in hypertensive or high-risk patients gradients in systolic blood pressure (SBP) accounted for most differences in outcome. To test whether our previous conclusions would hold, we updated our quantitative overview with new information from clinical trials published before 2005. To compare new and old antihypertensive drugs, we computed pooled odds ratios from stratified 2 × 2 contingency tables. In a meta-regression analysis, we correlated these odds ratios with corresponding between-group differences in SBP. We then contrasted observed odds ratios with those predicted from gradients in SBP. The main finding of our overview was that reduction in SBP largely explained cardiovascular outcomes in the recently published actively controlled trials in hypertensive patients and in placebo-controlled secondary prevention trials. The published results suggested that dihydropyridine calcium-channel blockers might offer a selective benefit in the prevention of stroke and inhibitors of the renin-angiotensin system in the prevention of heart failure. For prevention of myocardial infarction, the published results were more equivocal, because of the benefit of amlodipine over placebo or valsartan in 2 trials, whereas other placebo-controlled trials of calcium-channel blockers or angiotensin converting enzyme inhibitors did not substantiate the expected benefit with regard to cardiac outcomes. In conclusion, the hypothesis that new antihypertensive drugs might influence cardiovascular prognosis over and beyond their antihypertensive effect remains unproven. Our overview emphasizes the need of tight blood pressure control, but does not allow determining to what extent blood pressure must be lowered for optimal cardiovascular prevention.
Similar content being viewed by others
Article PDF
References
Prospective Studies Collaboration : Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903–1913.
Asia Pacific Cohort Studies Collaboration : Blood pressure and cardiovascular disease in the Asia Pacific region. J Hypertens 2003; 21: 707–716.
European Society of Hypertension/European Society of Cardiology Guidelines Committee : 2003 European Society of Hypertension/European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011–1053.
Chobanian AV, Bakris GL, Black BK, et al: The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 2003; 289: 2560–2572.
Staessen JA, Wang JG, Thijs L : Cardiovascular prevention and blood pressure reduction: a meta-analysis. Lancet 2001; 358: 1305–1315 ( erratum published in Lancet 2002; 359: 360).
Staessen JA, Wang JG, Thijs L : Calcium-channel blockade and cardiovascular prognosis: recent evidence from clinical outcome trials. Am J Hypertens 2002; 15: 85S–93S.
Staessen JA, Wang JG, Thijs L : Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until March 2003. J Hypertens 2003; 21: 1055–1076.
Borhani NO, Mercuri M, Borhani PA, et al: Final outcome results of the multicenter isradipine diuretic atherosclerosis study (MIDAS). A randomized controlled trial. JAMA 1996; 276: 785–791.
Hansson L, Lindholm LH, Niskanen L, et al: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611–616.
National Intervention Cooperative Study in Elderly Hypertensives Study Group : Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. Hypertension 1999; 34: 1129–1133.
Hansson L, Lindholm LH, Ekbom T, et al: Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354: 1751–1756.
Brown MJ, Palmer CR, Castaigne A, et al: Morbidity and mortality in patients randomised to double-blind treatment with long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS Study: Intervention as a Goal in Hypertensive Treatment (INSIGHT). Lancet 2000; 356: 366–372.
Hansson L, Hedner T, Lund-Johansen P, et al: Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356: 359–365.
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group : Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2000; 283: 1967–1975.
Agabiti Rosei E, Dal Palú C, Leonetti G, et al: Clinical results of the Verapamil in Hypertension and Atherosclerosis Study. J Hypertens 1997; 15: 1337–1344.
UK Prospective Diabetes Study Group : Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 2000; 317: 713–720.
Lindholm LH, Ibsen H, Dahlöf B, et al: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004–1010.
Dahlöf B, Devereux RB, Kjeldsen SE, et al: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995–1003.
Black HR, Elliott WJ, Grambsch P, et al: Principal results of the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) Trial. JAMA 2003; 289: 2073–2082.
Zanchetti A, Bond G, Hennig M, et al: Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis. Principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 2002; 106: 2422–2427.
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group : Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–2997.
Zanchetti A, Bond MG, Hennig M, et al: Risk factors associated with alterations in carotid intima-media thickness in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis. J Hypertens 1998; 16: 949–961.
Wing LMH, Reid CM, Ryan P, et al: A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348: 583–592.
Lithell H, Hansson L, Skoog I, et al: The study on cognition and prognosis in the elderly (SCOPE). Principal results of a randomised double-blind intervention trial. J Hypertens 2003; 21: 875–886.
Bulpitt CJ, Beckett NS, Cooke J, et al: Results of the pilot study for the Hypertension in the Very Elderly Trial. J Hypertens 2003; 21: 2409–2417.
Zanchetti A, Agabiti Rosei E, Dal Palú C, et al: The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. J Hypertens 1998; 16: 1667–1676.
Helgeland A : Treatment of mild hypertension: a five year controlled drug trial. Am J Med 1980; 69: 725–732.
Black HR, Elliott WJ, Neaton JD, et al: Baseline characteristics and early blood pressure control in the CONVINCE trial. Hypertension 2001; 37: 12–18.
Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al: A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary heart disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290: 2805–2816.
Malacco E, Mancia G, Rappelli A, et al: Treatment of isolated systolic hypertension: the SHELL study results. Blood Press 2003; 12: 160–167.
Agodoa LY, Appel L, Bakris GL, et al: Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis. JAMA 2001; 285: 2719–2728.
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group : Diuretic versus α-blocker as first step antihypertensive therapy. Final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension 2003; 42: 239–246.
Lewis EJ, Hunsicker LG, Clarke WR, et al: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–860.
Rodby RA, Rohde RD, Clarke WR, et al: The Irbesartan Type II Diabetic Nephropathy Trial: study design and baseline patient characteristics. Nephrol Dial Transplant 2000; 15: 487–497.
Berl T, Hunsicker LG, Lewis JB, et al: Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Arch Intern Med 2003; 138: 542–549.
Julius S, Kjeldsen SE, Brunner H, et al: VALUE Trial: long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. Am J Hypertens 2003; 16: 544–548.
Mann J, Julius S, for the VALUE Trial Group : The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) Trial of cardiovascular events in hypertension. Rationale and design. Blood Press 1998; 7: 176–183.
Kjeldsen SE, Julius S, Brunner H, et al: Characteristics of 15 314 hypertensive patients at high coronary risk. The VALUE Trial. Blood Press 2001; 10: 83–91.
Julius S, Kjeldsen SE, Weber M, et al: Outcomes in hypertensive patients at high cardiovascular risk treated with valsartan- or amlodipine-based regimens: VALUE, a randomised trial. Lancet 2004; 363: 2022–2031.
Weber MA, Julius S, Kjeldsen SE, et al: Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004; 363: 2049–2051.
Nissen SE, Tuzcu EM, Libby P, et al: Effect of antihypertensive agents on cardiovascular events in patients with coronary heart disease and normal blood pressure. The CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2217–2226.
Byington RB, Miller ME, Herrington D, et al: Rationale, design, and baseline characteristics of the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT). Am J Cardiol 1997; 80: 1087–1090.
Pitt B, Byington RP, Furberg CD, et al: Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 2000; 102: 1503–1510.
Poole-Wilson PA, Lubsen J, Kirwan BA, et al: Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet 2004; 364: 849–857.
Lubsen J, Poole-Wilson PA, Pocock SJ, et al: Design and current status of ACTION: A Coronary disease Trial Investigating Outcome with Nifedipine GITS. Eur Heart J 1998; 19 ( Suppl I): I20–I32.
Dens JA, Desmet WJ, Coussement P, et al: Usefulness of nisoldipine for prevention of restenosis after percutaneous transluminal coronary angioplasty (results of the NICOLE study). NIsoldipine in COronary artery disease in LEuven. Am J Cardiol 2001; 87: 28–33.
Dens JA, Desmet WJ, Coussement P, et al: Long term effects of nisoldipine on the progression of coronary atherosclerosis and the occurrence of clinical events: the NICOLE study. Heart 2003; 89: 887–892.
Teo KK, Burton JR, Buller CE, et al: Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis. The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). Circulation 2000; 102: 1748–1754.
The European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease Investigators : Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary heart disease: randomised double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782–788.
Neal B, MacMahon S, on behalf of the PROGRESS Management Committee : The PROGRESS study: rationale and design. J Hypertens 1995; 13: 1869–1873.
PROGRESS Collaborative Group : Randomised trial of a perindopril-based blood pressure lowering regimen among 6105 individuals with prior stroke or transient ischaemic attack. Lancet 2001; 358: 1033–1041.
Lièvre M, Marre M, Chatellier G, et al: The non-insulin-dependent diabetes, hypertension, microalbuminuria or proteinuria, cardiovascular events, and ramipril (DIABHYCAR) study: design, organization, and patient recruitment. Control Clin Trials 2000; 21: 383–396.
Marre M, Lièvre M, Vasmant D, et al: Determinants of elevated urinary albumin in the 4,937 type 2 diabetic subjects recruited for the DIABHYCAR study in Western Europe and Northern Africa. Diabet Care 2000; 23 ( Suppl 2): B40–B48.
Marre M, Lievre M, Chatellier G, et al: Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). BMJ 2004; 328: 495–501 ( erratum published in BMJ 2004; 328: 686).
The Heart Outcomes Prevention Evaluation Study Investigators : Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145–153.
Heart Outcomes Prevention Evaluation Study Investigators : Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253–259.
MacMahon S, Sharpe N, Gamble G, et al: Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. J Am Coll Cardiol 2000; 36: 438–443.
The PEACE Trial Investigators : Angiotensin-converting-enzyme inhibition in stable coronary heart artery disease. N Engl J Med 2004; 351: 2058–2068.
PROGRESS Collaborative Group : Effects of perindopril-based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease. Eur Heart J 2003; 24: 475–484.
Wright JT Jr, Bakris G, Greene T, et al: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. Results from the AASK trial. JAMA 2002; 288: 2421–2431.
Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW : The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998; 338: 645–652.
Estacio RO, Savage S, Nagel NJ, Schrier RW : Baseline characteristics of participants in the Appropriate Blood Pressure Control in Diabetes trial. Control Clin Trials 1996; 17: 242–257.
Estacio RO, Jeffers BW, Gifford N, Schrier RW : Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabet Care 2000; 23 ( Suppl 2): B54–B64.
Schrier RW, Estacio RO : Additional follow-up from the ABCD trial in patients with type 2 diabetes and hypertension. N Engl J Med 2000; 343: 1969.
Schrier RW, Estacio RO, Esler A, Mehler P : Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002; 61: 1086–1097.
Ruggenenti P, Remuzzi G, on behalf of the Bergamo Diabetic Nephrologic Study Group : Primary prevention of renal failure in diabetic patients: the Bergamo Nephrologic Diabetes Complications Trial. J Hypertens 1998; 16: S95–S97.
Ruggenenti P, Fassi A, Parvanova Ilieva A, et al: Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351: 1941–1951.
Mogensen CE, Neldam S, Tikkanen I, et al: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria study (CALM) study. BMJ 2000; 321: 1440–1444.
Parving HH, Lehnert H, Bröchner-Mortensen J, et al: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870–878.
Levey AS, Greene T, Schluchter MD, et al: Glomerular filtration rate measurements in clinical trials. J Am Soc Nephrol 1993; 4: 1159–1171.
Brenner BM, Cooper ME, de Zeeuw D, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–869.
Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group : The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456–1462.
Hansson L, Hedner T, Lindholm L, et al: The Captopril Prevention Project (CAPPP) in hypertension —baseline data and current status. Blood Press 1997; 6: 365–367.
Mancia G, Brown M, Castaigne A, et al: Outcomes with nifedipine GITS or co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT). Hypertension 2003; 41: 431–436.
UK Prospective Diabetes Study Group : Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703–713.
Hansson L, Zanchetti A, Carruthers SG, et al: Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755–1762.
SHEP Cooperative Research Group : Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255–3264.
Curb JD, Pressel SL, Cutler JA, et al: Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA 1996; 276: 1886–1892.
Liu L, Wang JG, Gong L, Liu G, Staessen JA, for the Systolic Hypertension in China (Syst-China) Collaborative Group : Comparison of active treatment and placebo in older patients with isolated systolic hypertension. J Hypertens 1998; 16: 1823–1829.
Wang JG, Staessen JA, Gong L, Liu L, for the Systolic Hypertension in China (Syst-China) Collaborative Group : Chinese trial on isolated systolic hypertension in the elderly. Arch Intern Med 2000; 160: 211–220.
Staessen JA, Fagard R, Thijs L, et al: Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350: 757–764 ( erratum published in Lancet 1997; 350: 1636).
Tuomilehto J, Rastenyte D, Birkenhäger WH, et al: Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 1999; 340: 677–684.
Staessen JA, Thijs L, Birkenhäger WH, Bulpitt CJ, Fagard R, on behalf of the Syst-Eur Investigators : Update on the Systolic Hypertension in Europe (Syst-Eur) Trial. Hypertension 1999; 33: 1476–1477.
PATS Collaborative Group : Post-stroke antihypertensive treatment study. A preliminary result. Chin Med J 1995; 108: 710–717.
PROGRESS Management Committee : PROGRESS —Perindopril Protection against Recurrent Stroke Study: characteristics of the study population at baseline. J Hypertens 1999; 17: 1647–1655.
Coope J, Warrender TS : Randomised trial of treatment of hypertension in elderly patients in primary care. BMJ 1986; 293: 1145–1151.
Management Committee : The Australian Therapeutic Trial in Mild Hypertension. Lancet 1980; i: 1261–1267.
Amery A, Birkenhäger W, Brixko P, et al: Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1985; i: 1349–1354.
European Working Party on High Blood Pressure in the Elderly (EWPHE) : An international trial of antihypertensive therapy in elderly patients. Objectives, protocol and organization. Arch Intern Pharmacodyn Ther 1985; 275: 300–334.
Hypertension-Stroke Cooperative Study Group : Effect of antihypertensive treatment on stroke recurrence. JAMA 1974; 229: 409–418.
Medical Research Council Working Party : MRC trial of treatment of mild hypertension: principal results. BMJ 1985; 291: 97–104.
MRC Working Party : Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992; 304: 405–412.
Dahlöf B, Lindholm LH, Hansson L, Scherstén B, Ekbom T, Wester PO : Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991; 338: 1281–1285.
Gong L, Zhang W, Zhu Y, et al: Shanghai trial of nifedipine in the elderly (STONE). J Hypertens 1996; 14: 1237–1245.
US Public Health Service Hospitals Cooperative Study Group (McFate Smith WM) : Treatment of mild hypertension: results of a ten-year intervention trial. Circ Res 1977; 40: I-98–I-105.
Veterans Administration Cooperative Study Group on Antihypertensive Agents : Effect of treatment on morbidity in hypertension: results in patients with diastolic blood pressure averaging 115–129 mmHg. JAMA 1967; 202: 116–122.
Kuramoto K, Matsushita S, Kuwajima I, Murakami M : Prospective study on the treatment of mild hypertension in the aged. Jpn Heart J 1981; 22: 75–85.
Wolff FW, Lindeman RD : Effects of treatment in hypertension: results of a controlled study. J Chron Dis 1966; 19: 227–240.
Carter AB : Hypotensive therapy in stroke survivors. Lancet 1970; 1: 485–489.
Veterans Administration-NHLBI Study Group for Cooperative Studies on Antihypertensive Therapy : Mild Hypertension (Perry HM Jr): Treatment of mild hypertension: preliminary results of a two-year feasibility trial. Circ Res 1977; 40: I-180–I-187.
Veterans Administration Cooperative Study Group on Antihypertensive Agents : Effects of treatment on morbidity in hypertension II. Results in patients with diastolic blood pressure averaging 90 through 114 mmHg. JAMA 1970; 213: 1143–1152.
Hypertension Detection and Follow-Up Program Cooperative Group : Five-year findings of the Hypertension Detection and Follow-Up Program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA 1979; 242: 2562–2571.
Hypertension Detection and Follow-Up Program Cooperative Group : Five-year findings of the Hypertension Detection and Follow-Up Program. III. Reduction in stroke incidence among persons with high blood pressure. JAMA 1982; 247: 633–638.
Casiglia E, Spolaore P, Mazza A, et al: Effect of 2 different therapeutic approaches on total and cardiovascular mortality in a cardiovascular study in the elderly. Jpn Heart J 1994; 35: 589–600.
Staessen JA, Wang JG : Blood-pressure lowering for the secondary prevention of stroke. Lancet 2001; 358: 1026–1027.
Dahlöf B, Devereux R, de Faire U, et al: The Losartan Intervention For Endpoint reduction (LIFE) in hypertension study: rationale, design and methods. Am J Hypertens 1997; 10: 705–713.
Lindholm LH, Ibsen H, Borch-Johnsen K, et al: Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 2002; 20: 1879–1886.
Hansson L, Lithell H, Skoog I, et al: Study on COgnition and Prognosis in the Elderly (SCOPE). Blood Press 1999; 8: 177–183.
Lithell H, Hansson L, Skoog I, et al: The Study on COgnition and Prognosis in the Elderly (SCOPE): outcomes in patients not receiving add-on therapy after randomisation. J Hypertens 2004; 22: 1605–1612.
Wright JT, Kusek JW, Toto RD, et al: Design and baseline characteristics of participants in the African American Study of Kidney disease and hypertension (AASK) pilot study. Control Clin Trials 1996; 16: 3S–16S.
World Health Organization–International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration : Protocol for prospective collaborative overviews of major randomized trials of blood-pressure-lowering treatments. J Hypertens 1998; 16: 127–137.
Blood Pressure Lowering Treatment Trialists' Collaboration : Effects of ACE inhibitors, calcium antagonists, and other blood pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000; 355: 1955–1964.
Blood Pressure Lowering Treatment Trialists' Collaboration : Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362: 1527–1535.
Wright JT Jr, Agodoa L, Contreras G, et al: Successful blood pressure control in the African American Study of Kidney Disease and Hypertension. Arch Intern Med 2002; 162: 1636–1643.
Reugg UT, Wallnofer A, Weir S, Cauvin C : Receptor-operated calcium-permeable channels in vascular smooth muscle. J Cardiovasc Pharmacol 1989; 14 ( Suppl 6): S49–S58.
Eriksson S, Olofsson BO, Wester PO, for the TEST Study Group : Atenolol in the secondary prevention of stroke. Cerebrovasc Dis 1995; 5: 21–25.
Bronner LL, Kanter DS, Manson JE : Primary prevention of stroke. N Engl J Med 1995; 333: 1392–1400.
Management Committee on behalf of the High Blood Pressure Research Council of Australia : Australian comparative outcome trial of angiotensin-converting enzyme inhibitor- and diuretic-based treatment of hypertension in the elderly (ANBP2): objectives and protocol. Clin Exp Pharmacol Physiol 1997; 24: 188–192.
Yui Y, Sumiyoshi T, Kodama K, et al: Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary heart disease: the Japan multicenter investigation for cardiovascular diseases-B (JMIC-B) randomized trial. Hypertens Res 2004; 27: 181–191.
Sever PS, Dahlöf B, Poulter NR, et al: Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. J Hypertens 2001; 19: 1139–1147.
Sever PS, Dahlöf B, Poulter NR, et al: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOTT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149–1158.
Rousseau MF, Melin J, Benedict CR, et al: Effects of nisoldipine therapy on myocardial perfusion and neuro-humoral status in patients with severe ischaemic left ventricular dysfunction. Eur Heart J 1994; 15: 957–964.
Thrackray S, Witte K, Clark AL, Cleland JGF : Clinical trials update: OPTIME-CHF, PRAISE-2, ALLHAT. Eur J Heart Failure 2000; 2: 209–212.
Packer M, O'Connor CM, Ghali JK, et al: Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996; 335: 1107–1114.
Figulla HR, Gietzen F, Zeymer U, et al: Diltiazem improves cardiac function and exercise capacity in patients with idiopathic dilated cardiomyopathy. Results of the Diltiazem in Dilated Cardiomyopathy Trial. Circulation 1996; 94: 346–352.
The Danish Study Group on Verapamil in Myocardial Infarction : Secondary prevention with verapamil after myocardial infarction. Am J Cardiol 1990; 66: 33I–40I.
Cleland JGF, Swedberg K, Poole-Wilson PA : Successes and failures in current treatment of heart failure. Lancet 1998; 652 ( Suppl 1): 9–28.
Yusuf S, Pfeffer MA, Swedberg K, et al: Effects of candesartan in patients with chronic heart failure and preserved left-ventricular systolic function: the CHARM-Alternative trial. Lancet 2003; 362: 777–781.
Granger CB, McMurray JJV, Yusuf S, et al: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362: 772–776.
McMurray JJV, Östergren J, Swedberg K, et al: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362: 767–771.
White HD : Should all patients with coronary heart disease receive angiotensin-converting-enzyme inhibitors? Lancet 2003; 362: 755–757.
Pitt B, Poole-Wilson PA, Segal R, et al: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial. The Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582–1587.
Dickstein K, Kjekshus J, the OPTIMAAL Steering Committee, for the OPTIMAAL Study Group : Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 2002; 360: 752–760.
Cohn JN, Tognoni G, for the Valsartan Heart Failure Trial Investigators : A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667–1675.
Pfeffer MA, McMurray JJV, Velazquez EJ, et al: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893–1906.
Packer M, Meller J, Gorlin R, Herman MV : Hemodynamic and clinical tachyphylaxis to prazosin-mediated after load reduction in severe chronic congestive heart failure. Circulation 1979; 59: 531–539.
Lund-Johansen P : Intensive blood pressure lowering treatment: beneficial for all but the smoking hypertensives? J Hypertens 2003; 21: 697–700.
Black HR, Elliott WJ, Neaton JD, et al: Rationale and design for the controlled onset verapamil investigation of cardiovascular endpoints (CONVINCE) trial. Control Clin Trials 1998; 19: 370–390.
Staessen J, Amery A, Fagard R : Editorial review. Isolated systolic hypertension in the elderly. J Hypertens 1990; 8: 393–405.
Franklin SS, Larson MG, Khan SA, et al: Does the relation of blood pressure to coronary heart disease change with aging? The Framingham Heart Study. Circulation 2001; 103: 1245–1249.
ACE Inhibitor Myocardial Infarction Collaborative Group : Indications for ACE inhibitors in the early treatment of acute myocardial infarction. Systematic overview of individual patient data in randomized trials. Circulation 1998; 97: 2202–2212.
Borghi C, Bacchelli S, Degli Esposti D, et al: Effects of the administration of an angiotensin-converting enzyme inhibitor during the acute phase of myocardial infarction in patients with arterial hypertension. Am J Hypertens 1999; 12: 665–672.
Materson BJ, Reda DJ, Cushman WC, et al: Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. N Engl J Med 1993; 328: 914–921.
Sareli P, Radevski IV, Valtchanova ZP, et al: Efficacy of different drug classes used to initiate antihypertensive treatment in black subjects. Results of a randomized trial in Johannesburg, South Africa. Arch Intern Med 2001; 161: 965–971.
Dickerson JEC, Hingorani AD, Ashby MJ, Palmer CR, Brown MJ : Optimisation of antihypertensive treatment by crossover rotation of four major drug classes. Lancet 1999; 353: 2008–2013.
Brown MJ, Cruickshank JM, Dominiczak AF, et al: Better blood pressure control: how to combine drugs? J Hum Hypertens 2003; 17: 81–86.
Adrougué HJ, Wilson H, Boyd AE, Suki WN, Eknoyan G : Plasma acid-base patterns in diabetic ketoacidosis. N Engl J Med 1982; 307: 1603–1610.
Staessen JA, Wang JG, Birkenhäger WH : Outcome beyond blood pressure control? Eur Heart J 2003; 24: 504–514.
Dalmay F, Mazouz H, Allard J, Pesteil F, Achard JM, Fournier JM : Non-AT1-receptor mediated protective effect of angiotensin against acute ischaemic stroke in the gerbil. J Renin Angiotensin Aldosterone Syst 2001; 2: 103–106.
Celentano A, Palmieri V, Di Palma Esposito N, et al: Relations of pulse pressure and other components of blood pressure to preclinical echocardiographic abnormalities. J Hypertens 2002; 20: 531–537.
de Simone G, Palmieri V, Bella JN, et al: Association of left ventricular hypertrophy with metabolic risk factors: the HyperGEN study. J Hypertens 2002; 20: 323–331.
Rothwell PM : External validity of randomised controlled trials: “to whom do the results of the trial apply?” Lancet 2005; 365: 82–93.
Staessen JA, Thijs L, Fagard R, et al: Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. J Hypertens 2004; 22: 847–857.
Mancia G, Bombelli M, Lanzarotti A, et al: Systolic vs diastolic blood pressure control in the hypertensive patients of the PAMELA population. Pressioni Arteriose Monitorate E Loro Associazioni. Arch Intern Med 2002; 162: 582–586.
Fagard RH, Van den Enden M : Treatment and blood pressure control in isolated systolic hypertension vs diastolic hypertension in primary care. J Hum Hypertens 2003; 17: 681–687.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Staessen, J., Li, Y., Thijs, L. et al. Blood Pressure Reduction and Cardiovascular Prevention: An Update Including the 2003–2004 Secondary Prevention Trials. Hypertens Res 28, 385–407 (2005). https://doi.org/10.1291/hypres.28.385
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1291/hypres.28.385
Keywords
This article is cited by
-
Predictors of Control Status of Hypertension in India: A Systematic Review and Meta-analysis
Journal of Prevention (2024)
-
Statistical reanalysis of vascular event outcomes in primary and secondary vascular prevention trials
BMC Medical Research Methodology (2021)